Recent Updates
Recently added Catalysts

Cetylpyridinium chloride

Phase 3

Healthy | Small molecule | Other |Sanofi|Last Updated: Mar 4, 2009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

Clinical trial landscape

Cetylpyridinium chloride · 2 trials · 2 indications

Phase 3 2
NCT00729599Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.Hygiene
COMPLETED31 Analytics
NCT00687037Safety Oral Mucosa Evaluation - Acceptability With Odontological Follow up - Cepacol Canela PowerHealthy
COMPLETED30 Analytics
PHASE3COMPLETED
Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.
Hygiene
NCT0072959931
Unlock trial analytics
PHASE3COMPLETED
Safety Oral Mucosa Evaluation - Acceptability With Odontological Follow up - Cepacol Canela Power
Healthy
NCT0068703730
Unlock trial analytics

Study Endpoints

Primary Endpoints

Patients will be evaluated according to the adverse reactions and the intensity of them.
21 days
Patients will be evaluated according to the adverse reactions and the intensity of them. The volunteers will also answer a questionnaire about the physical attributes of the product.
21 days
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALCetylpyridinium chloride during 21 consecutive days.
IEXPERIMENTALCetylpyridinium chloride during 21 days.

Interventions

NameTypeDescription
Cetylpyridinium chlorideDRUGCetylpyridinium chloride during 21 consecutive days.
Unlock Study Design Details

Eligibility Criteria

Age Range10 Years to 60 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Integral buccal mucous (without oral pathologies); * Normal odontological exams; Exclusion Criteria: * Lactation or gestational risk or gestation; * Use of Antiinflammatory or immunosuppression drugs 15 days before the study; * Being in odontological treatment; * Pathologica...

Countries:Brazil
Unlock Eligibility Criteria

Frequently asked questions about Cetylpyridinium chloride

What is Cetylpyridinium chloride used for?

Cetylpyridinium chloride is a small molecule being developed by Sanofi for healthy and hygiene indications. It is an investigational drug that has been studied in clinical trials for oral mucosa and dermatological safety evaluations. The drug is currently in Phase 3 clinical development.

Who makes Cetylpyridinium chloride?

Cetylpyridinium chloride is being developed by Sanofi, a company listed on the stock exchange under the ticker SNY. Sanofi is the developer of this small molecule drug, which is being studied for healthy and hygiene indications.

What phase is Cetylpyridinium chloride in?

Cetylpyridinium chloride is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for healthy and hygiene indications by its developer, Sanofi.

What clinical trials is Cetylpyridinium chloride in?

Cetylpyridinium chloride has been studied in two completed Phase 3 clinical trials. One trial, NCT00687037, evaluated safety and acceptability of Cepacol Canela Power in healthy adults in Brazil. Another trial, NCT00729599, evaluated safety and acceptability of Cepacol Teen in individuals aged 10 years and older in Brazil.

Is Cetylpyridinium chloride the same as Cepacol?

Cetylpyridinium chloride is associated with the Cepacol brand name. Clinical trials for the drug were conducted using products named Cepacol Canela Power and Cepacol Teen. These trials evaluated the safety and acceptability of the drug in healthy and hygiene contexts.